Understanding G-CSF and bone pain

Dr Jasmine Ramiah eases the distress of experiencing bone pain after receiving a granulocyte colony-stimulating factor (G-CSF) injection.

Granulocyte colony-stimulating factor (G-CSF) is one of oncology’s silent yet impactful heroes. There are several indications and whether used after chemotherapy or for stem cell mobilisation, G-CSF significantly reduces the risk of febrile neutropenia (fever and low neutrophil count) or termed neutropenic sepsis by stimulating the bone marrow to produce neutrophils. There are, however, unwarranted uncomfortable side effect profiles which include bone pain.

What is G-CSF?

G-CSF is a haematopoietic growth factor implicated in proliferation and differentiation of neutrophil precursors in the bone marrow. Common preparations include filgrastim, lenograstim, and pegfilgrastim. 

The indications for these agents include the routine administration following myelosuppressive chemotherapy to reduce infection risk and maintain dose intensity.

By accelerating bone marrow recovery, G-CSF allows you to recover your individual white cell count (WCC) therefore resuming the chemotherapeutic regimens. This, however, comes at a price and your clinician needs to balance the clinical indication versus toxicity profiles.

Why does bone pain occur?

Bone pain associated with G-CSF is reported, according to the literature, in up to 20–40% of patients and is dependent on both the dosing and formulation. The pathophysiology is not fully elucidated, but several mechanisms are proposed:

1. Marrow expansion: G-CSF stimulates rapid proliferation of granulocyte precursors. This increased cellular activity within the confined medullary expanse may raise intraosseous pressure, resulting in discomfort. 

2. Cytokine release: G-CSF induces secondary inflammatory mediators, such as interleukins and prostaglandins, which may sensitise nociceptors within bone causing discomfort and pain.

3. Stem cell mobilisation effects: In higher-dose settings (peripheral blood stem cell collection), pain may be more pronounced due to intense marrow stimulation.

The pain typically described by patients is a deep, aching, or pressure-like sensation and most commonly affects the sternum, pelvis, lower back, and long bones; areas rich in proliferative capacity and active marrow.

When does it happen?

The symptoms typically occur within 24–72 hours of administration and may last several days. Pegylated formulations, due to their longer half-life, can produce more prolonged symptoms in some patients.

Importantly, patients must be informed that the bone pain is generally self-limiting and not indicative of pathology, such as metastases, but rather indicative of the activity of the drugs. 

The utility of G-CSF is limited in myeloid malignancies owing to the potential stimulation of the initial clone. 

Management strategies

Reassurance is key. Educating patients before administration significantly reduces anxiety if pain develops and assists with tolerance.

First-line treatment typically includes paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) if platelet count allows and may be escalated according to the pain ladder.

In cases of more severe discomfort, antihistamines such as loratadine have been explored, based on the hypothesis of histamine-mediated pathways, though evidence remains mixed. Short courses of opioids may be considered in select patients bearing in mind the side effect profiles.

Conclusion

While G-CSF-related bone pain can be distressing, it is usually transient and manageable for the majority of patients.

Importantly, its presence reflects active marrow recovery rather than a pathological process, such as metastases or disease recurrence, and may be viewed as a positive sign that the body is responding to treatment. 

Proactive education, early symptom management and intervention, and reassurance remain the cornerstone in optimising patient experience during supportive oncology care.

Dr Jasmine Ramiah is a clinical haematology subspecialist at Inkosi Albert Luthuli Central Hospital. She expanded her expertise and qualified as a haematopathologist in 2024. This dual training has sharpened her diagnostic acumen and enriched her clinical perspective, allowing her to integrate precise pathology insights with patient-centred haematology care.

Header image by Freepik